Brilinta® (ticagrelor) – New indication
November 6, 2020 - AstraZeneca announced the FDA approval of Brilinta (ticagrelor), to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score 5) or high-risk transient ischemic attack (TIA).
Download PDF
